Clinical Trial Update: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of combining everolimus with eribulin in patients with triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Halaven (eribulin)

Snippet

Sponsor: Istituti Ospitalieri di Cremona | Conditions: Triple Negative Breast Cancer | Phase 1 | Status: UNKNOWN